The role of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer

Ann Transl Med. 2023 Jan 15;11(1):27. doi: 10.21037/atm-22-5266. Epub 2023 Jan 6.

Authors

Jorge Avila^{1

2}, José Pablo Leone³

Affiliations

¹ Department of Internal Medicine, St. Elizabeth's Medical Center, Boston, MA, USA.
² Department of Medicine, Tufts University School of Medicine, Boston, MA, USA.
³ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

No abstract available

Keywords: Antibody drug conjugates; overall survival (OS); targeted therapy.

Publication types

Editorial
Comment